Fig. 4: GSK-3β inhibitor TWS119 reverses CELSR2 KD-induced proliferation inhibition in glioma cells.
From: Atypical cadherin CELSR2 acts as a therapeutic target for glioma through WNT3A/β-catenin signaling
A, B Cultured U87 MG cells transfected with CELSR2-shRNA were treated without or with TWS119 (CELSR2 KD or KD + TWS119), and cells without CELSR2-shRNA transfection were used as the control. EDU labeling showed a decrease in EDU+ cell density in the CELSR2-KD group compared to the control and the CELSR2 KD + TWS119 group. C, D Flow cytometry of cultured cells revealed an increase in the G0/G1 phase and a decrease in the S phase in the CELSR2-KD group compared to the control and the CELSR2 KD + TWS119 group. E, F Western blots showed lower expression of β-catenin and p-GSK-3β and higher expression of p-β-catenin and GSK-3β in the CELSR2-KD group compared to the control and the CELSR2 KD + TWS119 group. Scale bar is 50 μm in (A). Data are represented as mean ± SEM. *P < 0.05; **P < 0.01; three independent experiments in each group; one-way ANOVA analysis of variance with Tukey’s multiple comparison.
